Please login to the form below

Not currently logged in
Email:
Password:

New global role for Shanahan at FD

Founder of Santé Communications, Liz Shanahan, has been appointed global head of healthcare and life sciences for medical communications firm FD

Founder of Santé Communications, Liz Shanahan, has been appointed global head of healthcare and life sciences for medical communications firm FD.

Shanahan will lead FD's team of cross-practice experts who serve healthcare and life sciences clients across the company's global network. She will work with the regional heads and the heads of FD's healthcare and life sciences sector teams building from a base of about 50 specialist consultants worldwide.

Her focus will be on leveraging new opportunities across the group and developing FD's health and life science's offering in new markets and identifying ways of adding value for existing clients.

Shanahan founded Santé Communications in 1995 and her company joined FD four years ago as FD Santé.

Liz Shanahan
Liz Shanahan

Commething on her appointment, Shanahan said: "This is a tremendous opportunity and an exciting challenge. In the past 10 years the healthcare and pharmaceutical sector has become increasingly globalised. While the US and the EU remain dominant we see, for example, increasing activity in the Asia Pacific region.

"Across the world, the industry operates within many different national constraints but globally it shares the challenges of increasing pressure on medicine and technology access, escalating R&D costs with reduced output and ever increasing regulatory pressures. Dozens of pharmaceutical companies and healthcare providers, large and small already trust FD with their most important products on communication."

18th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics